Integration of radiotherapy and immunotherapy for treatment of oligometastases

• Published in: The lancet oncology Vol. 20; no. 8; pp. e434 - e442
• Main Authors: Pitroda, Sean P, MD, Chmura, Steven J, MD, Weichselbaum, Ralph R, Prof
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.08.2019; Elsevier Limited
• Subjects: Cancer therapies; Chemotherapy; Clinical outcomes; Hematology, Oncology, and Palliative Medicine; Hypotheses; Immune checkpoint inhibitors; Immunotherapy; Integration; Metastases; Metastasis; Oncology; Patients; Pharmaceuticals; Prostate; Radiation therapy; Surgery; Survival; Tumors; Virulence
• ISSN: 1470-2045; 1474-5488
• DOI: 10.1016/S1470-2045(19)30157-3

SummaryMetastasis is the leading cause of cancer-related mortality and remains one of the prevailing challenges in cancer treatment. Most patients with metastatic disease are treated with systemic agents, which prolong survival and improve symptoms but are typically not curative. The oligometastatic hypothesis challenges the perspective that metastasis is an invariably disseminated process, and proposes a biological spectrum of metastatic virulence. Mounting evidence supports the idea that patients with numerically and spatially restricted sites of metastases, termed oligometastases, can achieve prolonged survival following metastasis-directed therapies, such as surgery or radiotherapy. Improvements in clinical and molecular staging of metastatic disease, as well as integration of effective systemic therapies with localised interventions, might achieve better outcomes for patients with diverse metastatic states. In this Series paper, we propose a rationale for the integration of immune checkpoint inhibitors with radiotherapy to advance the potential for effective treatment along the spectrum of disease, with emphasis on how immunotherapy can potentiate radiotherapy treatment in the oligometastatic setting.